Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00376285

Enrollment

Registered

2006-09-14

Start date

2006-11-30

Completion date

Unknown

Last updated

2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

Interventions

DRUGCP-742,033

DRUGFenofibrate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI of 30-40 kg/m2

Exclusion criteria

* Women of childbearing potential

Design outcomes

Primary

Measure	Time frame
Toleration and safety	—

Secondary

Measure	Time frame
Efficacy biomarkers, serum lipids	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026